Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Evaluation of a hypoxia regulated gene panel in ovarian cancer.

Baker AF, Malm SW, Pandey R, Laughren C, Cui H, Roe D, Chambers SK.

Cancer Microenviron. 2015 Apr;8(1):45-56. doi: 10.1007/s12307-015-0166-x. Epub 2015 May 22.

2.

Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK.

Cancer Prev Res (Phila). 2014 Sep;7(9):896-905. doi: 10.1158/1940-6207.CAPR-13-0408. Epub 2014 Jun 20.

3.

Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Gruessner C, Gruessner A, Glaser K, Abushahin N, Laughren C, Zheng W, Chambers SK.

Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014.

4.

Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.

Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK.

Invest New Drugs. 2013 Feb;31(1):160-6. doi: 10.1007/s10637-012-9827-5. Epub 2012 May 13.

5.

Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS.

Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261. Epub 2012 Mar 15.

Supplemental Content

Loading ...
Support Center